DOC4281 ERNDIM Critical Errors in Qualitative schemes 2022



Administration Office

Administration Office c/o EMQN CIC Third Floor, ICE Building, 3 Exchange Quay, Salford M5 3ED, United Kingdom. Tel: +44 161 757 4952

Critical Errors in the 2023 Qualitative EQA schemes

All critical errors for the 2023 schemes were agreed at the SAB online meeting held on 30th November and 1st December 2023.

EQA scheme]				
Scheme Name ¹	Sample Number	Scheme Year	Diagnosis	Critical Error	Number of Labs	No of participants ²	% (
AAI -				The participant interpreted the changes as a result of a liver dysfunction. The			0.8
		2023		recommendations for further examinations did not take an inborn disorder of metabolism			
	2023-02		Adenosine kinase deficiency	into consideration.	1	127	
			·				3.1
		2023		Four critical errors were agreed for suggesting mild hyperhomocysteinaemia, a normal			
	2023-05		Remethylation defect (CbIC disease)	profile, or wrong diagnosis, without a further recommendation to clarify the findings	4	127	
ACDB Heidelberg	2023-A	2023	Glutaric acidemia type 1 (common sample)	Failure to report C5DC or a related ratio and did not report any diagnosis.	1	40	2.5
	2023-B	2023	3-Methylglutaconic aciduria type I	Did not report elevated ACs also did not report a diagnosis.	2	40	5.0
	2023-D	2023	· •	Two participants stated the acylcarnitine profile not to be representative for an	3	40	7.5%
			Propionic acidemia, PA	organoaciduria or fatty acid metabolism defect and provided alternative possible			
				disorders. One failed to provide any diagnosis.			
	2023-E	2023	Very long-chain acyl CoA dehydrogenase (VLCAD) deficiency)	40	5.0%
				One participant commented on slightly elevated C14 carnitine but categorized it as not			
				relevant for a pathologic condition and opted for a normal acylcarnitine profile. Another			
				participant reported several numeric concentrations for various acylcarnitines but did not			
				categorize the findings or give a diagnosis.			
ACDB London	2023-A	2023	Glutaric Acidaemia Type 1 OMIM 231670	Did not detect glutaryl carnitine, did not suggest GA1 as a diagnosis.	1	42	2.49
	2023-F	2023	Methylmalonyl CoA mutase deficiency (MMA) OMIM 251000	Did not detect increased C3 carnitine.	1	42	2.4%
ACDB Rome	-	2023	-	-	0	43	0.09
CDG	-	2023		-	0	52	0.0%
DPT CH	2023-C	2023	Alkaptonuria (OMIM #203500)	Incorrect diagnosis provided.	1	21	4.8%
DPT CZ	2023-E	2023	Phenylketonuria due to phenylalanine hydroxylase deficiency.	Failure to recognize abnormal excretion of phenylalanine and/or its metabolites, which	1	19	5.3%
				prevented establishing the correct diagnosis.			
DPT FR	-	2023	-	-	0	19	0.0%
DPT NL	-	2023	-	-	0	18	0.0%
DPT UK	-	2023	-	-	0	19	0.0%
QLOU Barcelona	2023-A	2023	Medium chain acyl-CoA dehydrogenase (MCAD) deficiency	Reported a normal profile and made no recommendations for further testing.	4	74	5.4%
	2023-D	2023	3-hydroxy-3-methylglutaryl-CoA lyase deficiency	Reported the diagnosis of 3-methylcrotonylglicinuria or 3-methylglutaconic aciduria type I	3	74	4.1%
				and not identify the increase of 3-hydroxy-3-methylglutarate.			
					1		1
	2023-E	2023	L-2-hydroxyglutaric aciduria	Reported the diagnosis of multyple acyl-CoA dehydrogenase deficiency without	1	74	1.49
			, ,,	information regarding neither alternative diagnosis or recommendation.			
QLOU Heidelberg						1	
	2023-C	2023	MSUD	One participant suggested a ketogenesis defect as principal diagnosis, another lab	2	73	2.79
				reported lactic aciduria (although both labs managed to find two key metabolites each).			
		2022		Reported only on elevated lactic acid, mentioned lactic acidemia with possible pyruvate	1 .	†	4 421
	2023-E	2023	PKU	dehydrogenase phosphatase deficiency	1	73	1.49
QLOU Sheffield	2023-B	2023	Methylmalonic Aciduria	Incorrect analytical findings and diagnosis.	1	71	1.49
	2023-F	2023	Alkaptonuria	Failed to detect the large peak of homogentisic acid and as a result did not make the			1
				correct diagnosis.	1	71	1.49
UMPS	2023-C	2023	MPS-III	Reporting a normal profile.	1	81	1.29
•				Totals		699	4.49

Notes

^{1.} AAI = Amino Acids Interpretation; ACDB = Acylcarnitines in DBS; CDG = Congenital Disorders of Glycoslylation; DPT = Diagnostic Proficiency Testing; CH = Switzerland; CZ = Czech Republic; FR = France; NL = Netherlands; UK = United Kingdom; QLOU = Qualitative Organic Acid; UMPS = Urine Mucopolysaccharides

^{2.} Number of participants = number of registered labs minus any Educational participants, non- or partial submitters and any labs that withdrew from the scheme